Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Data Show Potential of mRNA to Produce Therapeutic and Protective Protein Levels in Pre-Clinical Models of Acute Intermittent Porphyria

By Moderna, Inc. | October 9, 2018

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new pre-clinical research published in the journal Nature Medicine that further demonstrates the utility of its mRNA platform to express therapeutic levels of protein in liver tissue to potentially treat patients with rare metabolic disorders

The paper, published in collaboration with researchers from the Center for Applied Medical Research (CIMA) at the University of Navarra, Pamplona, Spain, reported the therapeutic potential of mRNA in reconstituting a functional enzyme in pre-clinical models of acute intermittent porphyria (AIP). AIP is an inherited, rare metabolic disorder that is caused by a deficiency in the body’s ability to metabolize porphyrin precursors. People with the disease typically experience discrete episodes or “attacks” that can be life-threatening, with nausea and severe gastrointestinal and/or neuropathic pain.

“In these pre-clinical models, we’ve shown that mRNA has the potential to restore the enzymatic deficiency inside liver cells responsible for AIP and normalize markers of the disease during attacks,” said Paolo Martini, Ph.D., chief scientific officer, rare diseases. “These data further support our ongoing efforts in rare metabolic diseases where mRNA can allow a particular tissue to produce therapeutic levels of a functional protein.”

In the study, a single administration of mRNA encoding for human porphobilinogen deaminase (hPBGD), delivered in proprietary lipid nanoparticles, led to expression of hPBGD protein in mouse liver tissue in as little as two hours, with maintained activity throughout the entire duration of an induced attack. PBGD activity and porphyrin precursor levels were also shown to normalize. Protection against key hallmarks of the disease, including mitochondrial dysfunction, hypertension, pain and motor impairment, were also observed in mice that received hPBGD mRNA. The research also showed safety and sustained levels of PBGD expression after repeat dosing of hPBGD mRNA in non-human primates.

“Today’s treatments for AIP can help manage patient symptoms, but there remains a real need to address the underlying cause of the disease,” said Antonio Fontanellas, Ph.D., a porphyria researcher in the hepatology program at CIMA and a senior author on the paper. “This pre-clinical research on an mRNA approach for the treatment of AIP is encouraging because in the models it suggests that a single dose can quickly restore enzyme PBGD activity for the duration of a typical attack and that dosing can be repeated to prevent new crises.”

About CIMA

The Center for Applied Medical Research (CIMA) is the University of Navarra’s biomedical research institute. Its mission is to carry out translational research to a high standard of excellence, based on novel biological knowledge and aimed at finding therapeutic solutions to patients’ needs. CIMA collaborates with other research institutions, governments, biotech and pharmaceutical companies to get the essential synergy to reach patients with new therapeutic and diagnostic solutions.

(Source: Moderna, Inc.)


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE